Review
Open access
Aug 2026
Small-molecule inhibitors targeting the NLRP3 inflammasome: advances since mid-2023 and future perspectives.
This review summarizes recent advances in NLRP3 inflammasome inhibitors reported from mid-2023 to the beginning of 2026, with emphasis on clinical development status, patent landscapes, and structural classifications.
D. Jia, Yun-Lei Hou, Yue Wu et al.
· RSC Medicinal Chemistry · 0 citations